A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors

References

• P. Patel, S.K. Wahan, S. Vishakha, B.D. Kurmi, G.D. Gupta, H. Rajak, and V. Asati, Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent, preprint (2022). Available at https://www.eurekaselect.com/article/124766.
   Google Scholar
• Globacan: Global cancer observatory, https://gco.iarc.fr/today/fact-sheets-cancers. accessed August 30th 2022.
   Google Scholar
• R. Hai, D. Yang, F. Zheng, W. Wang, X. Han, A.M. Bode, and X. Luo, The emerging roles of HDACs and their therapeutic implications in cancer, Eur. J. Pharmacol. 931 (2022), pp. 175216. doi:10.1016/j.ejphar.2022.175216.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, T. Jha, and B. Ghosh, Dissecting histone deacetylase 3 in multiple disease conditions: Selective inhibition as a promising therapeutic strategy, J. Med. Chem. 64 (2021), pp. 8827–8869. doi:10.1021/acs.jmedchem.0c01676.
   PubMed Web of Science ®Google Scholar
• E. Seto and M. Yoshida, Erasers of histone acetylation: The histone deacetylase enzymes, Cold Spring Harb. Perspect. Biol. 6 (2014), pp. a018713. doi:10.1101/cshperspect.a018713.
   PubMed Web of Science ®Google Scholar
• S. Banerjee, N. Adhikari, S.A. Amin, and T. Jha, Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview, Eur. J. Med. Chem. 164 (2019), pp. 214–240. doi:10.1016/j.ejmech.2018.12.039.
   PubMed Web of Science ®Google Scholar
• C.-H.J. Chen, H. Jiang, O. Martin, and A.R. Wilson-Smith, Procedural and clinical outcomes of transcatheter aortic valve replacement in bicuspid aortic valve patients: A systematic review and meta-analysis, Ann. Cardiothorac. Surg. 11 (2022), pp. 351–362. doi:10.21037/acs-2022-bav-22.
   PubMedGoogle Scholar
• -L.-L. Cao 1, X. Song, L. Pei, L. Liu, H. Wang, and M. Jia, Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis, Medicine (Baltimore) 96 (2017), pp. e7663. doi:10.1097/MD.0000000000007663.
   PubMed Web of Science ®Google Scholar
• -L.-L. Zhang, Q. Li, D.-S. Zhong, W.-J. Zhang, X.-J. Sun, and Y. Zhu, MCM5 aggravates the HDAC1-mediated malignant progression of lung cancer, Front. Cell. Dev. Biol. 9 (2021), pp. 669132. doi:10.3389/fcell.2021.669132.
   PubMedGoogle Scholar
• N. Zhang, H. Zhang, Y. Liu, P. Su, J. Zhang, X. Wang, M. Sun, B. Chen, W. Zhao, L. Wang, H. Wang, M.S. Moran, B.G. Haffty, and Q. Yang, SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2, Cell Death Differ. 26 (2019), pp. 843–859. doi:10.1038/s41418-018-0158-8.
   PubMed Web of Science ®Google Scholar
• S. Nagarajan, S.V. Rao, J. Sutton, D. Cheeseman, S. Dunn, E.K. Papachristou, J.-E. Gonzalez Prada, D.-L. Couturier, S. Kumar, K. Kishore, C.S. Reddy Chilamakuri, S.-E. Glont, E.A. Goode, C. Brodie, N. Guppy, R. Natrajan, A. Bruna, C. Caldas, A. Russell, R. Siersbæk, K. Yusa, I. Chernukhin, and J.S. Carroll, ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response, Nat. Genet. 52 (2020), pp. 187–197. doi:10.1038/s41588-019-0541-5.
   PubMed Web of Science ®Google Scholar
• N. Injinari, Z. Amini-Farsani, M. Yadollahi-Farsani, and H. Teimori, Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer, Life Sci. 269 (2021), pp. 119027. doi:10.1016/j.lfs.2021.119027.
   PubMed Web of Science ®Google Scholar
• Y. Zhang, D.A. Nalawansha, K.E. Herath, R. Andrade, and M.K.H. Pflum, Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping, Mol. Omics. 17 (2021), pp. 544–553. doi:10.1039/d0mo00047g.
   PubMed Web of Science ®Google Scholar
• X. Liu, Y. Yu, J. Zhang, C. Lu, L. Wang, P. Liu, and H. Song, HDAC1 silencing in ovarian cancer enhances the chemotherapy response, Cell Physiol. Biochem. 48 (2018), pp. 1505–1518. doi:10.1159/000492260.
   PubMedGoogle Scholar
• T. Lv, K. Song, L. Zhang, W. Li, Y. Chen, Y. Diao, Q. Yao, and P. Liu, miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1, Biochem. Cell Biol. 96 (2018), pp. 663–671. doi:10.1139/bcb-2018-0031.
   PubMedGoogle Scholar
• W. Xiong, S. Yang, W. Zhang, Y. Chen, and F. Wang, MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1, Pharmazie 74 (2019), pp. 111–114. doi:10.1691/ph.2019.8756.
   PubMed Web of Science ®Google Scholar
• M.W. Shin, S.L. Kim, H.C. Yang, S.K. Yim, S.Y. Seo, S.T. Lee, H.-K. Kim, and S.-W. Kim, The HDAC1 inhibitor CBUD-1001 enhances TRAIL-induced apoptosis in colorectal cancer cells, Anticancer Res. 41 (2021), pp. 4353–4364. doi:10.21873/anticanres.15240.
   PubMed Web of Science ®Google Scholar
• C. Chen, M. Wei, C. Wang, D. Sun, P. Liu, X. Zhong, Q. He, and W. Yu, The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer, Gene 754 (2020), pp. 144851. doi:10.1016/j.gene.2020.144851.
   PubMed Web of Science ®Google Scholar
• Z. Yu, J. Zeng, H. Liu, T. Wang, Z. Yu, and J. Chen, Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs, Oncol. Let. 17 (2019), pp. 3296–3304. doi:10.3892/ol.2019.9962.
   PubMed Web of Science ®Google Scholar
• J. Sun, J. Piao, N. Li, Y. Yang, K.-Y. Kim, and Z. Lin, Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer, FEBS J. 287 (2020), pp. 2118–2133. doi:10.1111/febs.15122.
   PubMed Web of Science ®Google Scholar
• H.J. Xie, J.H. Noh, J.K. Kim, K.H. Jung, J.W. Eun, H.J. Bae, M.G. Kim, Y.G. Chang, J.Y. Lee, H. Park, and S.W. Nam, HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer, PLoS One 7 (2012), pp. e34265. doi:10.1371/journal.pone.0034265.
   PubMed Web of Science ®Google Scholar
• W.-B. Yang, -C.-C. Hsu, T.-I. Hsu, J.-P. Liou, K.-Y. Chang, P.-Y. Chen, -J.-J. Liu, S.-T. Yang, J.-Y. Wang, S.-H. Yeh, R.-M. Chen, W.-C. Chang, and J.-Y. Chuang, Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma, Neuro. Oncol. 22 (2020), pp. 1439–1451. doi:10.1093/neuonc/noaa103.
   PubMed Web of Science ®Google Scholar
• Y. Huang, J. Chen, C. Lu, J. Han, G. Wang, C. Song, S. Zhu, C. Wang, G. Li, J. Kang, and J. Wang, HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation, Cell Death Dis. 5 (2014), pp. e1491. doi:10.1038/cddis.2014.433.
   PubMed Web of Science ®Google Scholar
• P.-C. Pao, D. Patnaik, L.A. Watson, F. Gao, L. Pan, J. Wang, C.N. Adaikkan, J. Penney, H.P. Cam, W.-C. Huang, L. Pantano, A. Lee, A. Nott, T.X. Phan, E. Gjoneska, S. Elmsaouri, S.J. Haggarty, and L.-H. Tsai, HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer’s disease, Nat. Commun. 11 (2020), pp. 2484. doi:10.1038/s41467-020-16361-y.
   PubMed Web of Science ®Google Scholar
• X. Xu, X. He, Z. Zhang, Y. Chen, J. Li, S. Ma, Q. Huang, and M. Li, CREB inactivation by HDAC1/PP1γ contributes to dopaminergic neurodegeneration in Parkinson’s disease, J. Neurosci. 42 (2022), pp. 4594–4604. doi:10.1523/JNEUROSCI.1419-21.2022.
   PubMed Web of Science ®Google Scholar
• L. Göschl, T. Preglej, N. Boucheron, V. Saferding, L. Müller, A. Platzer, K. Hirahara, H.-Y. Shih, J. Backlund, P. Matthias, B. Niederreiter, A. Hladik, M. Kugler, G.A. Gualdoni, C. Scheinecker, S. Knapp, C. Seiser, R. Holmdahl, K. Tillmann, R. Plasenzotti, B. Podesser, D. Aletaha, J.S. Smolen, T. Karonitsch, G. Steiner, W. Ellmeier, and M. Bonelli, Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis, J. Autoimmun. 108 (2020), pp. 102379. doi:10.1016/j.jaut.2019.102379.
   PubMed Web of Science ®Google Scholar
• J. Yang, M.-Y. Zhang, Y.-M. Du, X.-L. Ji, and Y.-Q. Qu, Identification and validation of CDKN1A and HDAC1 as senescence-related hub genes in chronic obstructive pulmonary disease, Int. J. Chron. Obstruct. Pulmon. Dis. 17 (2022), pp. 1811–1825. doi:10.2147/COPD.S374684.
   PubMed Web of Science ®Google Scholar
• X.-Q. Wang, H.-M. Bai, S.-T. Li, H. Sun, L.-Z. Min, -B.-B. Tao, J. Zhong, and B. Li, Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells, Oncotarget 8 (2017), pp. 48027–48040. doi:10.18632/oncotarget.18227.
   PubMedGoogle Scholar
• J. Chen, L. Peng, Z. Zhao, Q. Yang, F. Yin, M. Liu, X. Luo, C. He, and Y. He, HDAC1 potentiates CD4+ T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus, Cell Immunol. 362 (2021), pp. 104284. doi:10.1016/j.cellimm.2021.104284.
   PubMed Web of Science ®Google Scholar
• S. Yoon and G.H. Eom, HDAC and HDAC inhibitor: From cancer to cardiovascular diseases, Chonnam. Med. J. 52 (2016), pp. 1–11. doi:10.4068/cmj.2016.52.1.1.
   PubMedGoogle Scholar
• J.-S. Chen, H.-K. Wang, C.-Y. Hsu, Y.-T. Su, J.-S. Chen, C.-L. Liang, P.C.-H. Hsieh, -C.-C. Wu, and A.-L. Kwan, HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis, Sci. Rep. 11 (2021), pp. 16354. doi:10.1038/s41598-021-95837-3.
   PubMed Web of Science ®Google Scholar
• J. Verma, V.M. Khedkar, and E.C. Coutinho, 3D-QSAR in drug design - A review, Curr. Top. Med. Chem. 10 (2010), pp. 95–115. doi:10.2174/156802610790232260.
   PubMed Web of Science ®Google Scholar
• G.-F. Yang and X. Huang, Development of quantitative structure-activity relationships and its application in rational drug design, Curr. Pharm. Des. 12 (2006), pp. 4601–4611. doi:10.2174/138161206779010431.
   PubMed Web of Science ®Google Scholar
• S.J.Y. Macalino, V. Gosu, S. Hong, and S. Choi, Role of computer-aided drug design in modern drug discovery, Arch. Pharm. Res. 38 (2015), pp. 1686–1701. doi:10.1007/s12272-015-0640-5.
   PubMed Web of Science ®Google Scholar
• D. Wei, T. Lu, D. Ma, K. Yu, T. Zhang, J. Xiong, W. Wang, Z. Zhang, Q. Fang, and J. Wang, Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition, Life Sci. 211 (2018), pp. 224–237. doi:10.1016/j.lfs.2018.09.040.
   PubMed Web of Science ®Google Scholar
• Y.-J. Chen, W.-H. Wang, W.-Y. Wu, -C.-C. Hsu, L.-R. Wei, S.-F. Wang, Y.-W. Hsu, -C.-C. Liaw, and W.-C. Tsai, Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways, PLoS One 12 (2017), pp. e0183368. doi:10.1371/journal.pone.0183368.
   PubMed Web of Science ®Google Scholar
• T.-Y. Lin, J. Fenger, S. Murahari, M.D. Bear, S.K. Kulp, D. Wang, C.-S. Chen, W.C. Kisseberth, and C.A. London, AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit, Blood 115 (2010), pp. 4217–4225. doi:10.1182/blood-2009-07-231985.
   PubMed Web of Science ®Google Scholar
• Y. Zhu, T. Yuan, Y. Zhang, J. Shi, L. Bai, X. Duan, R. Tong, and L. Zhong, AR-42: A pan-HDAC inhibitor with antitumor and antiangiogenic activities in esophageal squamous cell carcinoma, Drug Des. Devel. Ther. 13 (2019), pp. 4321–4330. doi:10.2147/DDDT.S211665.
   PubMed Web of Science ®Google Scholar
• D.R. Li, H. Zhang, E. Peek, S. Wang, L. Du, G. Li, and A.I. Chin, Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer, J. Urol. 194 (2015), pp. 547–555. doi:10.1016/j.juro.2015.02.2918.
   PubMed Web of Science ®Google Scholar
• R. Zhou, J. Wu, X. Tang, X. Wei, C. Ju, F. Zhang, J. Sun, D. Shuai, Z. Zhang, Q. Liu, and X.-B. Lv, Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU, Oncol. Lett. 16 (2018), pp. 1967–1974. doi:10.3892/ol.2018.8854.
   PubMed Web of Science ®Google Scholar
• A. Mims 1, A.R. Walker, X. Huang, J. Sun, H. Wang, R. Santhanam, A.M. Dorrance, C. Walker, P. Hoellerbauer, S.S. Tarighat, K.K. Chan, R.B. Klisovic, D. Perrotti, M.A. Caligiuri, J.C. Byrd, C.-S. Chen, L.J. Lee, S. Jacob, K. Mrózek, C.D. Bloomfield, W. Blum, R. Garzon, S. Schwind, and G. Marcucci, Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia, Leukemia 27 (2013), pp. 871–878. doi:10.1038/leu.2012.342.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ accessed October 15th 2022.
   Google Scholar
• S.G. Liva, C.C. Coss, J. Wang, W. Blum, R. Klisovic, B. Bhatnagar, K. Walsh, S. Geyer, Q. Zhao, R. Garzon, G. Marcucci, M.A. Phelps, and A.R. Walker, Phase I study of AR-42 and decitabine in acute myeloid leukemia, Leuk. Lymph. 61 (2020), pp. 1484–1492. doi:10.1080/10428194.2020.1719095.
   PubMedGoogle Scholar
• D.M. Lucas, L. Alinari, D.A. West, M.E. Davis, R.B. Edwards, A.J. Johnson, K.A. Blum, C.C. Hofmeister, M.A. Freitas, M.R. Parthun, D. Wang, A. Lehman, X. Zhang, D. Jarjoura, S.K. Kulp, C.M. Croce, M.R. Grever, C.-S. Chen, R.A. Baiocchi, and J.C. Byrd, The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo, PLoS One 5 (2010), pp. e10941. doi:10.1371/journal.pone.0010941.
   PubMed Web of Science ®Google Scholar
• S. Zhang, A. Suvannasankha, C.D. Crean, V.L. White, C.-S. Chen, and S.S. Farag, The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells, Int. J. Cancer 129 (2011), pp. 204–213. doi:10.1002/ijc.25660.
   PubMed Web of Science ®Google Scholar
• D.W. Sborov, A. Canella, E.M. Hade, X. Mo, S. Khountham, J. Wang, W. Ni, M. Poi, C. Coss, Z. Liu, M.A. Phelps, A. Mortazavi, L. Andritsos, R.A. Baiocchi, B.A. Christian, D.M. Benson, J. Flynn, P. Porcu, J.C. Byrd, F. Pichiorri, and C.C. Hofmeister, A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas, Leuk. Lymph. 58 (2017), pp. 2310–2318. doi:10.1080/10428194.2017.1298751.
   PubMed Web of Science ®Google Scholar
• J. Tng, J. Lim, K.-C. Wu, A.J. Lucke, W. Xu, R.C. Reid, and D.P. Fairlie, Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation, J. Med. Chem. 63 (2020), pp. 5956–5971. doi:10.1021/acs.jmedchem.0c00230.
   PubMed Web of Science ®Google Scholar
• M.J. Chua, J. Tng, E. Hesping, G.M. Fisher, C.D. Goodman, T. Skinner-Adams, D. Do, A.J. Lucke, R.C. Reid, D.P. Fairlie, and K.T. Andrews, Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice, Int. J. Parasitol. Drugs. Drug Resist. 17 (2021), pp. 118–127. doi:10.1016/j.ijpddr.2021.08.006.
   PubMed Web of Science ®Google Scholar
• ChemDraw Ultra 5.0, Cambridge Soft Corporation, USA, 2010; Available at http://www.cambridgesoft.com.
   Google Scholar
• Discovery Studio 3.0, Accelrys Inc., San Diego, USA, 2011; Available at http://www.accelrys.com.
   Google Scholar
• C.W. Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474. doi:10.1002/jcc.21707.
   PubMed Web of Science ®Google Scholar
• V. Yadav, S. Banerjee, S.K. Baidya, N. Adhikari, and T. Jha, Applying comparative molecular modelling techniques on diverse hydroxamate-based HDAC2 inhibitors: An attempt to identify promising structural features for potent HDAC2 inhibition, SAR QSAR Environ. Res. 32 (2021), pp. 835–861. doi:10.1080/1062936X.2021.1976831.
   PubMedGoogle Scholar
• K. Roy, S. Kar, and R.N. Das, A Primer on QSAR/QSPR Modeling: Fundamental Con- Cepts, Springer, New York, 2015.
   Google Scholar
• The simple, user-friendly, and reliable online standalone tools; Available at http://dtclab.webs.com/software-tools.
   Google Scholar
• D.A. Freedman, Statistical Models: Theory and Practice. A simple regression equation has on the right-hand side an intercept and an explanatory variable with a slope coefficient. A multiple regression e right-hand side, each with its own slope coefficient, Cambridge University Press, Cambridge, UK, 2009.
   Google Scholar
• S. Katoch, S.S. Chauhan, and V. Kumar, A review on genetic algorithm: Past, present, and future, Multimed. Tools Appl. 80 (2021), pp. 8091–8126. doi:10.1007/s11042-020-10139-6.
   PubMed Web of Science ®Google Scholar
• V. Kumar and K. Roy, Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases, SAR QSAR Environ. Res. 31 (2020), pp. 511–526. doi:10.1080/1062936X.2020.1776388.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S. Banerjee, S.K. Baidya, B. Ghosh, and T. Jha, Ligand-based quantitative structural assessments of SARS-CoV-2 3CL pro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences, J. Mol. Struct. 1251 (2022), pp. 132041. doi:10.1016/j.molstruc.2021.132041.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs, J. Mol. Struct. 1156 (2018), pp. 501–515. doi:10.1016/j.molstruc.2017.12.005.
   Web of Science ®Google Scholar
• S.K. Baidya, S.A. Amin, S. Banerjee, N. Adhikari, and T. Jha, Structural exploration of arylsulfonamide-based ADAM17 inhibitors through validated comparative multi-QSAR modelling studies, J. Mol. Struct. 1185 (2019), pp. 128–142. doi:10.1016/j.molstruc.2019.02.081.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Understanding chemico-biological interactions of glutamate MMP-2 inhibitors through rigorous alignment-dependent 3D-QSAR analyses, ChemistrySelect 2 (2017), pp. 7888–7898. doi:10.1002/slct.201701330.
   Web of Science ®Google Scholar
• S. Banerjee, S.A. Amin, S.K. Baidya, N. Adhikari, and T. Jha, Exploring the structural aspects of ureido-amino acid-based APN inhibitors: A validated comparative multi-QSAR modelling study, SAR QSAR Environ. Res. 31 (2020), pp. 325–345. doi:10.1080/1062936X.2020.1734080.
   PubMed Web of Science ®Google Scholar
• S. Guti, S.K. Baidya, S. Banerjee, N. Adhikari, and T. Jha, A robust classification-dependent multi-molecular modelling study on some biphenyl sulphonamide based MMP-8 inhibitors, SAR QSAR Environ. Res. 32 (2021), pp. 835–861. doi:10.1080/1062936X.2021.1976831.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64. doi:10.1016/j.molstruc.2017.04.020.
   Web of Science ®Google Scholar
• Golbraikh and A. Tropsha, Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection, Mol. Div. 5 (2000), pp. 231–243. doi:10.1023/A:1021372108686.
   Web of Science ®Google Scholar
• https://ccsb.scripps.edu/mgltools/ Accessed October 18th 2022.
   Google Scholar
• O. Trott and A.J. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, J. Comp. Chem. 31 (2010), pp. 455–461.
   PubMed Web of Science ®Google Scholar
• J. Eberhardt, D. Santos-Martins, A.F. Tillack, and S. Forli, AutoDock vina 1.2.0: New docking methods, expanded force field, and python bindings, J. Chem. Inf. Model. 61 (2021), pp. 3891–3898. doi:10.1021/acs.jcim.1c00203.
   PubMed Web of Science ®Google Scholar
• https://www.rcsb.org/ accessed October 18th 2022.
   Google Scholar
• H. Tang, X.S. Wang, X.-P. Huang, B.L. Roth, K.V. Butler, A.P. Kozikowski, M. Jung, and A. Tropsha, Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation, J. Chem. Inf. Model. 49 (2009), pp. 461–476. doi:10.1021/ci800366f.
   PubMed Web of Science ®Google Scholar
• J. Shi, G. Zhao, and Y. We, Computational QSAR model combined molecular descriptors and fingerprints to predict HDAC1 inhibitors, Médecine/Sciences 34 (2018), pp. 52–58. doi:10.1051/medsci/201834f110.
   Google Scholar
• H. Sirous, G. Campiani, V. Calderone, and S. Brogi, Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening, Comp. Biol. Med. 137 (2021), pp. 104808. doi:10.1016/j.compbiomed.2021.104808.
   PubMed Web of Science ®Google Scholar
• T. Abdizadeh, R. Ghodsi, and F. Hadizadeh, 3D-QSAR (CoMFA, CoMSIA) and molecular docking studies on histone deacetylase 1 selective inhibitors, Recent Pat. Anticancer Drug Discov. 12 (2017), pp. 365–383. doi:10.2174/1574892812666170508125927.
   PubMed Web of Science ®Google Scholar
• S. Krishna, A.D. Lakra, N. Shukla, S. Khan, D.P. Mishra, S. Ahmed, and M.I. Siddiqi, Identification of potential histone deacetylase1 (HDAC1) inhibitors using multistep virtual screening approach including SVM model, pharmacophore modeling, molecular docking and biological evaluation, J. Biomol. Struct. Dyn. 38 (2020), pp. 3280–3295. doi:10.1080/07391102.2019.1654925.
   PubMed Web of Science ®Google Scholar